Roche’s Evrysdi (risdiplam) granted FDA priority review for treatment of pre-symptomatic babies…
Roche announced that the U.S. Food and Drug Administration (FDA) has granted priority review of a supplemental new drug application (sNDA) for the use of Evrysdi (risdiplam) to treat…
Read More...
Read More...